Advertisement
The conference call may be accessed by dialing 877.874.1570 for domesticcallers and 719.325.4780 for international callers. Please specify to theoperator that you would like to join the "Arena Pharmaceuticals Third Quarter2008 Earnings Call." The conference call will be webcast live under theinvestor relations section of Arena's website at http://www.arenapharm.com,and will be archived there for 30 days following the call. Please connect toArena's website several minutes prior to the start of the broadcast to ensureadequate time for any software download that may be necessary.
Advertisement
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused ondiscovering, developing and commercializing oral drugs in four majortherapeutic areas: cardiovascular, central nervous system, inflammatory andmetabolic diseases. Arena's most advanced drug candidate, lorcaserin, is beinginvestigated in a Phase 3 clinical trial program for the treatment of obesity.Arena's broad pipeline of novel compounds target G protein-coupled receptors,an important class of validated drug targets, and includes compounds beingevaluated independently and with partners, including Merck & Co., Inc. andOrtho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of thecompany. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statementsthat involve a number of risks and uncertainties. Such forward-lookingstatements include statements about Arena's strategy, internal and partneredprograms, and ability to develop compounds and commercialize drugs. For suchstatements, Arena claims the protection of the Private Securities LitigationReform Act of 1995. Actual events or results may differ materially fromArena's expectations. Factors that could cause actual results to differmaterially from the forward-looking statements include, but are not limitedto, clinical trials and studies may not proceed at the time or in the mannerArena expects or at all, the results of clinical trials or preclinical studiesmay not be predictive of future results, Arena's ability to receive regulatoryapproval for its drug candidates, Arena's ability to partner lorcaserin,APD125, APD791 or other of its compounds or programs, the timing, success andcost of Arena's research, out-licensing endeavors and clinical trials, Arena'sability to obtain additional financing, Arena's ability to obtain and defendits patents, the timing and receipt of payments and fees, if any, from Arena'scollaborators, and Arena's ability to redeem with common stock any outstandingshares of its series B convertible preferred stock. Additional factors thatcould cause actual results to differ materially from those stated or impliedby Arena's forward-looking statements are disclosed in Arena's filings withthe Securities and Exchange Commission. These forward-looking statementsrepresent Arena's judgment as of the time of this release. Arena disclaims anyintent or obligation to update these forward-looking statements, other than asmay be required under applicable law.Contacts: Jack Lief Mary Claire Duch President and CEO WeissComm Partners Media Relations David Walsey 212.301.7228 Director, Corporate Communications Arena Pharmaceuticals, Inc. 858.453.7200, ext. 1682
SOURCE Arena Pharmaceuticals, Inc.
